EDGE MEDICAL-B Shares Surge Over 6% Following Regulatory Approval for Integrated Surgical Robot Platform

Stock News03-17 11:34

EDGE MEDICAL-B (02675) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 6.28%, trading at HK$57.5, with a turnover of HK$22.9121 million. The increase follows news that the company's fully self-developed "multi-port + single-port + remote" integrated surgical robot platform, described as the world's first and currently only one of its kind, has received market approval from the National Medical Products Administration (NMPA). This approval signifies a critical milestone for EDGE MEDICAL-B's "three-in-one" minimally invasive surgical innovation solution, marking its transition from technological exploration and product development to regulatory endorsement. It also represents a major breakthrough in platform innovation, system integration, and clinical application expansion for China's high-end surgical robotics sector. As the first company in China and the second globally to simultaneously obtain regulatory approval for multi-port, single-port laparoscopic, and natural orifice surgical robots, EDGE MEDICAL-B has established a comprehensive product portfolio. With the formal NMPA approval of the "three-in-one" platform, the company plans to further advance its dual-drive strategy focusing on remote operation and artificial intelligence.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122703872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 11:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122703872","market":"us","top_or_hot":-1,"title":"EDGE MEDICAL-B Shares Surge Over 6% Following Regulatory Approval for Integrated Surgical Robot Platform","media":"Stock News","content":"<p>EDGE MEDICAL-B (02675) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 6.28%, trading at HK$57.5, with a turnover of HK$22.9121 million. The increase follows news that the company's fully self-developed \"multi-port + single-port + remote\" integrated surgical robot platform, described as the world's first and currently only one of its kind, has received market approval from the National Medical Products Administration (NMPA). This approval signifies a critical milestone for EDGE MEDICAL-B's \"three-in-one\" minimally invasive surgical innovation solution, marking its transition from technological exploration and product development to regulatory endorsement. It also represents a major breakthrough in platform innovation, system integration, and clinical application expansion for China's high-end surgical robotics sector. As the first company in China and the second globally to simultaneously obtain regulatory approval for multi-port, single-port laparoscopic, and natural orifice surgical robots, EDGE MEDICAL-B has established a comprehensive product portfolio. With the formal NMPA approval of the \"three-in-one\" platform, the company plans to further advance its dual-drive strategy focusing on remote operation and artificial intelligence.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EDGE MEDICAL-B Shares Surge Over 6% Following Regulatory Approval for Integrated Surgical Robot Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEDGE MEDICAL-B Shares Surge Over 6% Following Regulatory Approval for Integrated Surgical Robot Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-17 11:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EDGE MEDICAL-B (02675) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 6.28%, trading at HK$57.5, with a turnover of HK$22.9121 million. The increase follows news that the company's fully self-developed \"multi-port + single-port + remote\" integrated surgical robot platform, described as the world's first and currently only one of its kind, has received market approval from the National Medical Products Administration (NMPA). This approval signifies a critical milestone for EDGE MEDICAL-B's \"three-in-one\" minimally invasive surgical innovation solution, marking its transition from technological exploration and product development to regulatory endorsement. It also represents a major breakthrough in platform innovation, system integration, and clinical application expansion for China's high-end surgical robotics sector. As the first company in China and the second globally to simultaneously obtain regulatory approval for multi-port, single-port laparoscopic, and natural orifice surgical robots, EDGE MEDICAL-B has established a comprehensive product portfolio. With the formal NMPA approval of the \"three-in-one\" platform, the company plans to further advance its dual-drive strategy focusing on remote operation and artificial intelligence.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1122703872","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122703872","pubTimestamp":1773718453,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"EDGE MEDICAL-B (02675) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 6.28%, trading at HK$57.5, with a turnover of HK$22.9121 million. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","ROBO":"全球机器人自动化ETF-ROBO","02675":"精锋医疗-B","BK1100":"医疗保健设备","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"集成手术机器人平台获得监管部门批准后，EDGE MEDICAL-B股价飙升超过6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02675":1,"VXUS":1,"ROBO":1},"content_text":"EDGE MEDICAL-B (02675) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 6.28%, trading at HK$57.5, with a turnover of HK$22.9121 million. The increase follows news that the company's fully self-developed \"multi-port + single-port + remote\" integrated surgical robot platform, described as the world's first and currently only one of its kind, has received market approval from the National Medical Products Administration (NMPA). This approval signifies a critical milestone for EDGE MEDICAL-B's \"three-in-one\" minimally invasive surgical innovation solution, marking its transition from technological exploration and product development to regulatory endorsement. It also represents a major breakthrough in platform innovation, system integration, and clinical application expansion for China's high-end surgical robotics sector. As the first company in China and the second globally to simultaneously obtain regulatory approval for multi-port, single-port laparoscopic, and natural orifice surgical robots, EDGE MEDICAL-B has established a comprehensive product portfolio. With the formal NMPA approval of the \"three-in-one\" platform, the company plans to further advance its dual-drive strategy focusing on remote operation and artificial intelligence.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122703872","isCrawlerRequest":true}